

## \$5m R&D tax incentive received

Genetic Signatures [ASX:GSS] (“GSS” or the “Company”), a global molecular diagnostics company, is pleased to announce that it has received a refund from the Australian Taxation Office under its Research and Development (“R&D”) tax incentive program in the amount of \$5,001,792.

The R&D tax incentive is an Australian Government program under which companies receive cash refunds for eligible Australian and international R&D activities during the financial year ended 30 June 2024.

### Authorisation and Additional Information

This announcement was authorised by the Board of Directors of Genetic Signatures Limited.

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

Allison Rossiter  
Chief Executive Officer

[allison.rossiter@geneticsignatures.com](mailto:allison.rossiter@geneticsignatures.com)  
T: +61 (0)2 9870 7580

Karl Pechmann  
Chief Financial and Operating Officer  
and Company Secretary  
[karl.pechmann@geneticsignatures.com](mailto:karl.pechmann@geneticsignatures.com)

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures’ proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen™* respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base®** technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.